The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Research > Xenometrix, Inc.

Xenometrix, Inc.
 PROFILE
Intensive care couldn't fully revive Xenometrix, which Discovery Partners International bought. The biotech firm, which makes testing systems that measure the side effects of certain drugs and the effects of chemicals on cells, had been undergoing financial challenges (the CEO even laid himself off) and had hoped restructuring and an infusion of licensing fees would help it rebound. The firm's Gene Profile Assays measure a gene's response to chemicals and compounds, and its Genotoxicity Assays measure compounds' carcinogenic potential. These products are sold to pharmaceutical, chemical, and biotech customers in the US, Europe, and Japan. The company is a subsidiary of Discovery Partners.

 COMPETITION
Aurora Biosciences Corporation (dossier)
Endogen, Inc. (dossier)
Gene Logic Inc. (GLGC)

 FINANCIAL OVERVIEW
Fiscal Year-End: June
2000 Sales (mil.): 1.90
1-Yr. Sales Growth: (40.2)%
Employees: 4
Revenue per employee: $475,000.00

 KEY PEOPLE
• Pauline Gee
    CEO
• Pauline Gee
    CFO

 CONTACT INFO
2425 N. 55th St., Ste. 111
Boulder, CO 80301
US
Phone: 303-447-1773
Fax: 303-447-1758
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001